Summary & Overview
CPT 81558: mRNA Gene Expression Profiling for Kidney Transplant Monitoring
CPT code 81558 designates a molecular diagnostic assay for kidney transplant surveillance: mRNA gene expression profiling of 139 genes from a whole blood specimen with an algorithmic interpretation that classifies patients as “transplant excellence” or “not transplant excellence.” This assay informs detection of subclinical rejection and monitoring of transplant stability, which can influence post‑transplant management and resource use across health systems. Nationally, molecular diagnostics like this are increasingly referenced in precision medicine and transplant care pathways.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage considerations and coding context relevant to these major public and commercial payers.
Readers will learn the clinical context of the assay, the typical laboratory service setting, and what the code represents in claims and billing workflows. The report summarizes benchmarks and policy‑relevant issues tied to algorithmic molecular diagnostics, highlights areas of payer coverage focus, and provides a concise reference for coding, clinical interpretation, and administrative handling. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 81558 describes an mRNA gene expression profiling assay performed on a whole blood specimen from a kidney transplant patient. The test measures expression of 139 genes by quantitative polymerase chain reaction (qPCR) and applies an algorithmic analysis combining patient data and test results to report a binary result: transplant excellence (indicative of stability) or not transplant excellence (indicative of subclinical rejection).
Service type: Laboratory — molecular diagnostic testing with algorithmic analysis (proprietary/diagnostic algorithm)
Typical site of service: Clinical laboratory or reference molecular diagnostics laboratory
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 52-year-old male kidney transplant recipient presents for routine post-transplant surveillance at an outpatient transplant clinic. The transplant team orders a whole blood test for mRNA gene expression profiling of 139 genes by quantitative polymerase chain reaction to assess for subclinical rejection. A phlebotomy draw is performed in the clinic; the specimen is sent to a certified molecular diagnostics laboratory. The laboratory technologist performs RNA extraction and qPCR on the whole blood sample, runs the validated 139-gene panel, and inputs the gene expression results along with relevant patient metadata (time from transplant, immunosuppressive regimen, prior biopsy results) into a proprietary algorithm. The analytic report yields a binary output: "transplant excellence" indicating immunologic stability, or "not transplant excellence" indicating potential subclinical rejection. The laboratory issues a final report to the transplant nephrologist and the electronic health record; clinical decisions (e.g., protocol biopsy, immunosuppression adjustment) are made by the treating team based on the report and other clinical data. Typical site of service is outpatient clinic or diagnostic laboratory processing center; service type is laboratory-based molecular diagnostic testing with algorithmic interpretation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional component of a test if applicable (e.g., physician interpretation billed separately). |